Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 does not affect viral response in patients treated with peginterferon alpha-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks.

Authors
  • Rodriguez-Torres, Maribel
  • Govindarajan, Sugantha
  • Diago, Moises
  • Morgan, Thomas
  • Anand, Bhupinderjit
  • Barange, Karl
  • Suter, Frank
  • Lin, Amy
  • Hooper, Gregory
  • Shiffman, Mitchell
Type
Published Article
Journal
Liver international : official journal of the International Association for the Study of the Liver
Publication Date
Feb 01, 2009
Volume
29
Issue
2
Pages
237–241
Identifiers
DOI: 10.1111/j.1478-3231.2008.01859.x
PMID: 18710427
Source
Medline
License
Unknown

Abstract

Steatosis did not influence the efficacy of treatment in our study population. Baseline viral load is a confounding factor, particularly in patients infected with genotype 3 and once baseline viral load was accounted for, the association between steatosis and SVR was not relevant.

Report this publication

Statistics

Seen <100 times